Laboratory research published in Frontiers reports that two cannabis-derived compounds, tetrahydrocannabinol (THC) and cannabidiol (CBD), produce strong anti-tumor effects against ovarian cancer cells in vitro. The investigators found that both agents reduced cancer cell proliferation, spread, and survival across multiple experimental measures.
Researchers tested THC and CBD on two ovarian cancer cell lines: one sensitive to platinum chemotherapy and one resistant. Both compounds killed cancer cells at concentrations much lower than those that harmed noncancerous cells, indicating selective cytotoxicity. The platinum-resistant line was more responsive at higher doses. When THC and CBD were combined in a 1:1 ratio, they acted synergistically and yielded stronger anticancer effects than either compound alone.
Key effects observed included a loss of clonogenic potential (the ability of cells to form new colonies), induction of apoptosis in roughly a quarter of cancer cells, reduced markers of metastatic potential, and inhibition of signaling pathways that drive tumor growth. The team reported that THC and CBD appear to downregulate the expression of proteins involved in these pathways, thereby dampening pro-growth signaling.
Lead author Siyao Tong, MD, said the findings are consistent with other preclinical work suggesting cannabinoids could complement conventional cancer therapies. Independent experts described the results as encouraging but emphasized that animal studies and clinical trials are needed before recommending cannabinoids as cancer treatments.
Beyond direct anticancer actions, both CBD and THC have established roles in symptom management—anti-nausea, anti-inflammatory, and analgesic effects—that can improve quality of life during cancer therapy. The authors propose that cannabinoids might be evaluated as adjuncts to platinum-based chemotherapy to help overcome chemoresistance while also alleviating treatment-related symptoms.
Ovarian cancer is the second most common gynecologic cancer in the United States and accounts for more deaths than any other cancer of the female reproductive system. In 2025 there were an estimated 20,000 cases and more than 12,000 deaths. Because symptoms are often vague and diagnosis frequently occurs at advanced stages, new therapeutic strategies are urgently needed.
The study strengthens the rationale for additional preclinical and clinical research into cannabinoids as complementary agents in ovarian cancer care, while underscoring that clinical recommendations must await validation in animal models and human trials.
